A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Trial Profile

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Sep 2017

At a glance

  • Drugs TSR 042 (Primary)
  • Indications Endometrial cancer; Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions; First in man; Registrational; Therapeutic Use
  • Acronyms GARNET
  • Sponsors TESARO
  • Most Recent Events

    • 12 Sep 2017 Preliminary results (n=33; part I and part IIA) assessing safety, efficacy, receptor occupancy and pharmacokinetics of TSR-042, presented at the 42nd European Society for Medical Oncology Congress.
    • 11 Sep 2017 According to a a TESARO media release, patients with microsatellite instability high (MSI-H) and microsatellite stable endometrial cancer and non-small cell lung cancer are currently enrolling in the expansion phase of this study, and additional tumor types are planned for evaluation.
    • 11 Sep 2017 Results published in a TESARO media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top